Coronavirus (COVID-19) Collection
Third wave of COVID-19 in Madrid, Spain
Madrid has been the epicenter of COVID-19 in Spain, primarily due to its high population density and mobility. The city has 3.3 million people, with 6.8 million across the metropolitan area. Up to March 15 2021, roughly 605 000 persons had been diagnosed with SARS-CoV-2 infection and 14 000 had died in the Madrid region (Ministerio de Sanidad, 2021; Instituto Nacional de Estadística, 2021). These figures refer to laboratory-confirmed cases, which underestimate the true number as testing access was limited during the earlier stages of the pandemic (Soriano and Barreiro, 2020).A call for strengthened evidence on targeted, non-pharmaceutical interventions against COVID-19 for the protection of vulnerable individuals in sub-Saharan Africa
A curious imbalance exists between the research and development (R&D) efforts dedicated to pharmaceutical versus non-pharmaceutical interventions in outbreak control. The scientific output as well as the associated R&D investments for pharmaceutical interventions are often a factor higher than those for non-pharmaceutical interventions, even though the latter commonly represent a cornerstone of outbreak control. This seems no different in the case of the coronavirus disease 2019 (COVID-19) pandemic: at the time of writing, a PubMed search indicated that the number of published peer-reviewed articles on COVID-19 and treatment/vaccination was approximately double that of COVID-19 and containment/prevention.
